Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $11.13.

Several research analysts recently issued reports on STRO shares. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Sutro Biopharma in a research report on Monday, November 18th. Wells Fargo & Company cut their price objective on Sutro Biopharma from $5.00 to $4.00 and set an "equal weight" rating for the company in a research report on Wednesday, December 11th. JMP Securities restated a "market outperform" rating and set a $17.00 price objective on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Finally, Wedbush restated an "outperform" rating and set a $8.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, December 10th.

Sutro Biopharma Price Performance

Shares of STRO stock traded up $0.05 during midday trading on Tuesday, reaching $1.79. 647,741 shares of the company traded hands, compared to its average volume of 953,859. Sutro Biopharma has a 1-year low of $1.51 and a 1-year high of $6.13. The firm has a market cap of $147.60 million, a PE ratio of -1.11 and a beta of 1.15. The firm's 50 day simple moving average is $1.96 and its two-hundred day simple moving average is $3.08.

Institutional Trading of Sutro Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of Sutro Biopharma by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company's stock valued at $6,426,000 after purchasing an additional 132,015 shares in the last quarter. State Street Corp lifted its stake in shares of Sutro Biopharma by 5.2% in the 3rd quarter. State Street Corp now owns 1,647,162 shares of the company's stock valued at $5,699,000 after purchasing an additional 81,855 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Sutro Biopharma by 15.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,136,457 shares of the company's stock valued at $2,091,000 after purchasing an additional 156,139 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Sutro Biopharma by 22.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,015,211 shares of the company's stock valued at $1,868,000 after purchasing an additional 187,114 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at about $2,852,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.